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A B S T R A C TObjective: We assessed the epidemiological and economic impact of a
quadrivalent human papillomavirus (HPV) (6/11/16/18) vaccine for
females in preventing cervical cancer, cervical intraepithelial neo-
plasia grades 2 and 3 (CIN 2/3), cervical intraepithelial neoplasia grade
1 (CIN 1), and genital warts in Japan by using a transmission
dynamic model. Methods: A published mathematical model of the
transmission dynamics of HPV infection and disease was adapted for
Japan. Model inputs were used from Japan or the Asia/Pacific region
when available; otherwise, the default values in the original model
were used. The transmission dynamic model was used to assess the
epidemiological and economic impact of a quadrivalent HPV (6/11/16/
18) vaccine for females in preventing cervical cancer, CIN 2/3, CIN 1,
and genital warts in Japan.Maintaining current cervical cancer screen-
ing practices, we evaluated two strategies: routine vaccination of
females by age 12 years (S1), and S1 combined with a temporary (5
years) female catch-up program for age 12 to 24 years (S2). The
vaccine coverage rate was 80% for the routine and 50% for the
catch-up vaccination programs. Results: Compared with no vaccina-
tion, both vaccination strategies significantly reduced the incidence ofsee front matter Copyright & 2013, International
r Inc.
.1016/j.vhri.2013.02.001
st: The authors have indicated that they have no
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ondence to: Kaoru Yamabe, MSD.K.K. 1-13-12 KudaHPV 6/11/16/18–related disease. The most effective strategy was S2. By
using this strategy over 100 years in the Japanese population, the
estimated cumulative percentage reduction in incident HPV 6/11/16/
18–related genital warts-female, genital warts-male, cervical CIN 1,
CIN 2/3, and cervical cancer cases was 90% (2,113,723 cases), 86%
(2,082,637 cases), 72% (263,406 cases), 71% (1,328,366 cases), and 58%
(323,145 cases), respectively. The cost-effectiveness ratios were JPY
1,244,000, and JPY 1,205,800 per quality-adjusted life-year gained for
S1 and S2 compared with no vaccination, respectively, over a time
horizon of 100 years. Conclusion: We conclude that a quadrivalent
HPV vaccination program for females can reduce the incidence of
cervical cancer, CIN, and genital warts in Japan at a cost-per-quality-
adjusted life-year ratio within the range defined as cost-effective.
Keywords: cervical intraepithelial neoplasia, cost-effectiveness analysis,
epidemiology, human papillomavirus, uterine cervical neoplasm,
vaccines.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In Japan as well as in the world, the second most common cancer
in women is cervical cancer after breast cancer. Each year,
approximately 10,000 cases are diagnosed, 3000 of which result
in death [1,2]. In 2004, the Ministry of Health, Labor and Welfare
introduced the screening test for women older than 20 years to
prevent cervical cancer; however, the screening rate is quite low
in comparison with other developed countries [3]. Cervical intra-
epithelial neoplasia (CIN) marks the precancerous stages of
cervical cancer, starting with the mild dysplasia (CIN 1), pro-
gressing to the more serious forms of CIN 2 and CIN 3, and finally
progressing to carcinoma. Cervical cancer is known to be caused
by infection with human papillomavirus (HPV) [4,5]. Although
more than 100 types of the virus have been identified [6], types 16
and 18 in particular are known to be oncogenic and associated
with about 70% of the cases of cervical cancer [7]. Infection with
the low-risk types of HPV 6 and 11 causes about 90% of the cases
of condylomata acuminatum (genital warts) [8]. In 2011, GARDA-
SIL was approved and is now available in Japan for females withthe indications for the prevention of the following diseases
caused by HPV types 6, 11, 16, and 18: cervical cancer (squamous
cell cancer and adenocarcinoma) and their precursor lesions (CIN
1/2/3 and cervical adenocarcinoma in situ), vulvar intraepithelial
neoplasma grade 1/2/3 and vagional intraepithelial neoplasma
grade 1/2/3, and genital warts (condyloma acuminate).
It is not mandatory to submit cost-effectiveness analysis
results for regulatory approval, and decision makers such as
government are not required to consider economic perspectives
when determining the value of drugs and funding financial
resources for vaccination programs in Japan. They have recently
become conscious, however, whether to be cost-effective or not
so as to allocate limited resources appropriately because of the
severe budget constraints and the coming superaged society that
will have to bear a significant increase in medical costs.
In this report, the authors review the results from a previously
developed health economic model [9] adapted to explore the
epidemiological and economic consequences of introducing a
quadrivalent HPV vaccine for females in Japan. Specifically, we
examined the potential population-level health impact of theSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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and genital warts, and associated health care costs from the
payer perspective. We also examined the cost-effectiveness of a
quadrivalent HPV vaccine program for females in Japan.Table 1 – Epidemiologic parameters.
Parameter Reference
Demographic parameters
Total population size 127,770,000 [23]
The female population of age 1
y and up (%)
45.9
The male population of age 12 y
and up (%)
43.2
Incidence of HPV-related diseases
Number of new cases of
cervical cancer
8,779 [24]
Number of cervical cancer
deaths
2,481 [24]
Number of new episodes of
anogenital wards
48,000 [23]
Females 21,120 [25]
Males 26,880
Screening, Clinical diagnosis, and treatment parameters
Age for Pap screening begins
(y)
20
Time interval between Pap test
(y)
2
Compliance with Pap screening 23.7 [3]
Female annual all-cause mortality by age
Age group (y) Mortality rate (%)
0–4 0.07
5–9 0.01
10–14 0.01
15–19 0.02
20–24 0.03
25–29 0.03
30–34 0.04
35–39 0.06
40–44 0.09 [22]
45–49 0.13
50–54 0.21
55–59 0.29
60–64 0.42
65–69 0.63
70–74 1.08
75–79 1.94
80–84 3.68
85–89 7.16
90–94 13.11
95–99 21.51
100þ 35.86
HPV, human papillomavirus; Pap, Papanicolaou.Methods
We adapted the previously developed mathematical model for
evaluating the impact of quadrivalent HPV vaccination in the
United States to explore the potential epidemiological and eco-
nomic impact of a quadrivalent HPV vaccine in Japan. The details
of this model and its structure have been previously described [9].
We modified components of the model for Japan and included
cervical cancer screening rates, treatment rates, and vaccination
strategies, as well as epidemiological (e.g., mortality) and eco-
nomic inputs. The following text describes the strategies eval-
uated, model parameters and outputs, the simulation method,
and the sensitivity and validation analyses.
Screening and Vaccination Strategies
Assumptions were that each vaccination strategy would be
combined with current cervical cancer screening rates and HPV
disease treatment practices in Japan. The base-case vaccination
strategy was the routine HPV vaccination of girls by age 12 years
(S1), and a catch-up vaccination program was added that targeted
girls and women 12 to 24 years of age in conjunction with the
base-case vaccination program for a period of just 5 years after
the initiation of the vaccination program (S2).
Model Parameters and Sources
We determined baseline assumptions and estimates by a com-
prehensive search of the literature, input from experts, and
analysis of clinical trial data [9]. Table 1 shows baseline epide-
miological parameters, and Table 2 shows economic parameters
and sources that we adopted.
Screening and Vaccination Program Strategy Parameters
We assumed that the period of protection for the HPV is lifetime
in the base case. It was also assumed that vaccination would not
have any effect on the natural course of any HPV infection that
may have been present at the time of vaccination. The HPV
vaccine was assumed to have an efficacy of 90% against cervical
cancer caused by HPV 6/11/16/18, 95.2% against all CIN caused by
HPV 6/11/16/18, and 98.9% against genital warts caused by HPV 6/
11 [9]. It was assumed that up to 80% of 12-year-old Japanese girls
would receive three doses and also the catch-up program for
12- to 24-year-old Japanese girls and women would receive 50%
coverage by year 5.
Economic Parameters
With regard to the economic perspective in this analysis, only
direct medical costs were considered. Therefore, the costs asso-
ciated with work and productivity losses were not included for the
analysis. Direct medical costs included the costs of vaccination,
cervical cancer screening, and diagnosis and treatment of
detected cervical cancer, CIN, and genital warts. We estimated
direct medical costs of interventions by using the Diagnosis
Procedure Combination (DPC). The cost of three-dose vaccine
was assumed as f36,000. Costs of conventional cytology screening
examinations, colposcopy, and biopsy were adopted from the
official code list of the DPC and the doctors’ fee schedule. Treat-
ment costs of genital warts were also calculated by the DPC and
confirmed by experts who were familiar with the treatment
options and utilization in Japan. The average per-patient costs ofthe diagnosis and treatment of precancerous states and cervical
cancer were calculated by the DPC (Table 2). Quality-adjusted life-
years (QALYs) were measured by using the health utility index by
weighting survival time by the quality-of-life adjustment
weights–associated time in all these health states over the plan-
ning horizon [9].
The planning horizon was 100 years, and it was assumed that
the population size over the 100-year horizon would be
113,843,070 (Japan population age 12 years and older in 2006).
The discount rate of all costs and effects was assumed 3% per
year in the base-case analysis.
Table 2 – Economic parameters.
Parameter Estimate
(JPY)
Reference
Cost of dfiagnosis and treatment
Cervical screening and visit 2,727
Coloscopy 1,887
Biopsy 18,113
CIN 1 episode-of-case 72,000
CIN 2/3 episode-of-case 185,940
Average cost per case of cervical
cancer by stage
LCC 1,744,760 [25]
RCC 2,742,550 [25]
DCC 3,513,270 [25]
Average cost per episode of
anogenitel warts
15,000
CIN 1, cervical intraepithelial neoplasia grade 1; CIN 2/3, cervical
intraepithelial neoplasia grades 2 and 3; DCC, distant cervical
cancer; LCC, localized cervical cancer; RCC, regional cervical cancer.
 5-y follow-up included.
Table 3 – Estimated cumulative reduction in HPV
types 6, 11, 16, 18–related disease cases from rou-
tine vaccination of females by age 12 y and a female
catch-up to age 24 y.
n
Over 5 y Over 25 y Over 100 y
Genital warts-female 14,212 400,479 2,113,723
Genital warts-male 8,139 386,551 2,082,637
CIN 1 254 35,745 263,406
CIN 2/3 802 146,763 1,328,366
Cervical cancer cases 1 10,985 323,145
Cervical cancer deaths 0 1430 88,441
Total 23,408 981,954 6,199,719
CIN 1, cervical intraepithelial neoplasia grade 1; CIN 2/3, cervical
intraepithelial neoplasia grades 2 and 3; HPV, human
papillomavirus.
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We used parameters to assess the epidemiological impact and
cost-effectiveness of both vaccination strategies. The epidemio-
logical outputs included invasive cervical cancer, CIN 2/3, CIN 1,
and genital warts cases, as well as cervical cancer deaths. The
outputs included total costs quality-adjusted survival and cost
per QALY. The incremental cost-effectiveness ratio (ICER) was
measured as the incremental cost between two strategies divided
by the incremental QALY between the two strategies.
Simulation Method
The quadrivalent HPV types 6/11/16/18 mathematical model was
developed as a series of differential equations in Mathematica
(Wolfram Research, Champaign, IL) and used the NDSolve sub-
routine in Mathematica version 7.0 to generate numerical sol-
utions for the differential equations of the model. The baseline
parameter estimates were used to solve the model for the
prevaccination state values of the variables. The prevaccination
status was used as the initial point for the vaccination model.
The entire time path of the variables was then considered until
the system approached a steady state at approximately 100 years.
This solution was used to generate the output described previ-
ously for each of the screening and vaccination strategies.
Validation Analyses
We have previously reported on validation of the natural history
component of the model [9,10]. The validity of the model was
adapted for Japanese consideration by comparing model predic-
tions to the epidemiological data found in the literature on the
incidence of cervical cancer in Japan [11].
Sensitivity Analysis
The results of sensitivity analysis from prior models [9,10,12]
were used to identify the most influential parameters to the
results. These parameters investigated in the sensitivity analysis
included duration of vaccine protection, vaccine coverage, vac-
cine efficacy against HPV 6/11–related disease, the discount rate,
and quality of life (i.e., health utilities). In addition, a pessimistic-
scenario sensitivity analysis was conducted with regard to theabove parameters that would be biased against vaccination. The
probabilistic sensitivity analysis is not included this time because
this model is transmission dynamic model.Results
Model Prediction
The prediction based on the model was that the incidence of HPV
16/18–related cervical cancer would be 9.4 per 100,000 among
girls and women aged 12 years older with current screening
strategies in the absence of vaccination. According to our esti-
mation, a crude rate was 15.1 for the incidence of cervical cancer
caused by all the HPV types in Japan for year 2007 [13]. It was
suggested that approximately 67% of all these cases are caused
by HPV 16/18 [13].
Finally, the model predicted an incidence of HPV 6/11–related
female genital warts of 40 per 100,000 among girls and women
aged 12 years and older in the absence of vaccination; however,
no population-level data are available on the incidence of genital
warts in the Japanese population.Epidemiologic Impact of the Vaccination Strategies
Compared with no vaccination, both vaccination strategies sig-
nificantly reduced the incidence of HPV 6/11/16/18–related dis-
ease (Fig. 1A–D, Table 1). The most effective strategy was
vaccination strategy S2 (routine vaccination of females by age
12 years combined with a temporary 5-year female catch-up
program for age 12–24 years). By using this strategy over 100 years
in the population of Japan, the estimated cumulative percentage
reduction in incident HPV 6/11/16/18–related genital warts-
female, genital warts-male, CIN 1, CIN 2/3, and cervical cancer
cases was 90% (2,113,723 cases out of 2,348,581), 86% (2,082,637
cases out of 2,421,670), 72% (263,406 cases out of 365,841), 71%
(1,328,366 cases out of 1,870,938), and 58% (323,145 cases out of
557,146), respectively (Table 3).Economic Impact of Vaccination Strategies
Table 4 presents the ICERs for the two vaccination strategies. The
ICERs were JPY 1,244,000 and JPY 1,205,800 per QALY gained for S1
and S2 compared with no vaccination, respectively (Table 4).
Fig. 1 – Estimated annual HPV related incidence by vaccination strategy in Japan.
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Table 5 describes the summary of results for the sensitivity
analyses we conducted. The pessimistic scenario biased against
vaccination was considered most influential. For this scenario,
we adopted 10 years for the protection period, lower quality-of-
life impact due to cervical dysplasia and genital warts, and 5% as
a discount rate. The ICER was influenced mostly by changing the
duration of vaccine protection.Discussion
We projected the potential epidemiological and economic impact
of the two HPV 6/11/16/18 vaccination strategies for females in
Japan by using a mathematical model. In the two vaccination
strategies evaluated, one targets 12-year-old girls as routine
vaccination and the other also includes a temporary 5-year
catch-up program for girls and women of age from 12 to 24
years. The results of this model suggested that the vaccineTable 4 – Cost-effectiveness analysis of HPV vaccination
Vaccination strategy Discount
Costs (JPY)
No vaccination 1,304,166,000
Routine vaccination by age 12 y 1,758,211,400
Routine vaccination by age 12 y þ temporary catch-up
for 12–24-year-olds
1,917,132,000
HPV, human papillomavirus; QALY, quality-adjusted life-year.
 Assumes cost of vaccination series is JPY 36,000 and the duration of p
y Compared with the preceding nondominated strategy.program for females can substantially reduce the incidence of
cervical cancer, CIN, and genital warts, improve quality of life and
survival, and be cost-effective in a setting of cervical cancer
screening in Japan. Specifically, it was demonstrated that the
quadrivalent HPV vaccination for 12-year-old girls or a routine
vaccination with a catch-up program can be cost-effective based
on the results from the model (f1,244,000/QALY and f1,205,800/
QALY, respectively). These are considered to be consistent with
other cost-effectiveness analyses generally presented that vacci-
nation for 12-year-old girls can be cost-effective [14,15]. For
decision makers of HPV vaccine policy in Japan as well as in
other countries, the above findings may be useful.
With regard to inclusion cost-effectiveness threshold, there
does not exist any clear threshold that is generally used in Japan
either for drugs or for vaccination programs. Accordingly, in the
current study, we utilized the cost-effectiveness criteria that the
World Health Organization established. When the ICER is within
one to three times the gross domestic product per capita, the
World Health Organization defines that the intervention is
considered as cost-effective [16]. Because the gross domesticstrategies (JPY/QALY).
ed total Incremental Incremental
(JPY)/QALYy
QALYs Costs (JPY) QALYs
2,680,111
2,680,476 454,045,400 365 1,244,000
2,680,619 612,966,000 508 1,205,800
rotection is lifelong. The discount rate was 3%.
Table 5 – Sensitivity analysis: incremental cost-
effectiveness ratios (JPY/QALY).
Vaccination strategy Routine vaccination by age
12 y þ catch-up between
ages 12 and 24 y
Base case 1,205,800
Coverage rate: 50% for routine
and 30% for catch-up
1,071,700
Discount rate: 1% 527,600
Discount rate: 5% 2,543,600
Duration of vaccine
protection: 10 y
3,651,200
Lower quality of life impact
due to cervical dysplasia
and genital warts
1,452,100
No 6/11 protection 1,596,400
Pessimistic scenario 7,436,700
QALY, quality-adjusted life-year.
 Pessimistic scenario was defined as duration of vaccine
protection as 10 y, lower quality-of-life impact due to cervical
dysplasia and genital warts, and 5% discount rate.
VA L U E I N H E A LT H R E G I O N A L I S S U E S 2 ( 2 0 1 3 ) 9 2 – 9 796product per capita of Japan in 2010 was approximately f3,758,000
[17], both the vaccination strategies would be regarded as cost-
effective according to these criteria. Furthermore, the two incre-
mental cost-effectiveness ratios are within the range of cost-
effectiveness ratios for other medical technologies that are
commonly accepted [18].
Although the economic evaluation of vaccines has not yet
been utilized over Japan, the situation is gradually changing.
Cost-effectiveness analysis can provide beneficial information for
decision makers such as the national and local governments
whether to fund financial resources for vaccination programs
from limited budget. The results of this analysis may help them
to decide for funding HPV vaccination programs that will reduce
the disease burden of HPV-related diseases among Japanese
females.
A key result from this analysis was that both vaccination
strategies can significantly reduce the burden of HPV disease in
the short term. The majority of the early reduction in HPV
disease seems to be provided from protection against HPV
6/11–related genital warts. The ratio of estimated cumulative
reduction in genital warts caused by HPV 6/11 is quite higher in
over 5 years than those of other periods (Table 3). We also
conducted sensitivity analyses to generate insights that would
be useful for developing an HPV vaccination policy. In the
sensitivity analysis, we identified the importance of the duration
of vaccine protection as one of the key variables. As the duration
of protection decreased, we found that the cost-effectiveness
ratios increased. It was also found that protection against genital
warts caused by HPV 6 and 11 was important to reduce the
burden of HPV diseases from this sensitivity analysis. For exam-
ple, the ICER for the routine with catch-up vaccination increased
approximately about 32% to JPY 1,596,400 per QALY gained,
assuming no protection against HPV 6/11 genital warts. For the
pessimistic scenario, finally, the cost-effectiveness ratio of the
catch-up strategy increased significantly to JPY 7,436,700 per
QALY gained in the sensitivity analysis. Among these parameters,
the ICER was influenced mostly by changing the duration of
vaccine protection, from lifelong (JPY 1,205,800/QALY) to 10 years
(JPY 3,651,200/QALY).
We have described five key limitations in the current study,
although the limitations of this model have been previously
described in detail [9]. First of all, although the model predictionsgenerally fell within the range of epidemiological values observed
for cervical cancer, unfortunately there exists no epidemiological
data on genital warts available for calibration in Japan. Second,
we modeled only four HPV disease types (6, 11, 16, and 18). This
study possibly provides a conservative estimation of both efficacy
and cost-effectiveness, because additional benefits that might be
realized through protection against HPV diseases associated with
infection due to other HPV types not directly targeted by the
vaccine (i.e., cross-protection) were not accounted for [19]. Third,
this study did not account for other potential benefits by HPV
vaccination that would have improved the cost-effectiveness
ratio, such as protection against vulvar and vaginal precancers
and cancers [20], protection against head and neck cancers [21],
protection against recurrent respiratory papillomatosis [22], and
mortality and productivity costs (i.e., indirect costs). Fourth, we
assumed that screening would not change over time with HPV
vaccination. Finally, we did not include death and adverse
reaction caused by vaccination.Conclusions
In conclusion, the results from this model suggest that in a
setting of cervical cancer screening in Japan, a prophylactic
quadrivalent HPV (6/11/16/18) vaccination program for females
can substantially reduce the incidence of cervical cancer, CIN,
and genital warts and improve quality of life and survival. From
an economic perspective, vaccination can be cost-effective when
implemented as a strategy that routinely vaccinates 12-year-old
females alone or in combination with catch-up for 12- to 24-year-
old females.
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